Ignet

Gene Information

Gene symbol: SDHC

Gene name: succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa

HGNC ID: 10682

Related Genes

#	Gene Symbol	Number of hits
1	CASP3	1 hits
2	SDHA	1 hits
3	SNAPC5	1 hits
4	TAF11	1 hits
5	TGFBI	1 hits

Related Sentences

#	PMID	Sentence
1	3180135	The molecular weights of these proteins observed are 68kd, 46kd, 28kd, 24kd, 19kd, and 15kd indicating that gag, env, and pX gene products are present.
2	19060140	Recently, a Fur-regulated sRNA, NrrF, was identified that is involved in the iron regulation of the sdhA and sdhC succinate dehydrogenase genes.
3	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
4	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
5	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
6	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
7	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
8	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
9	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.
10	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
11	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
12	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
13	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
14	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
15	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
16	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.
17	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
18	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
19	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
20	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
21	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
22	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
23	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.
24	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
25	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
26	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
27	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
28	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
29	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
30	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.
31	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
32	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
33	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
34	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
35	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
36	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
37	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.
38	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
39	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
40	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
41	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
42	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
43	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
44	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.
45	22159511	In a previous study, we constructed a recombinant caspase-3 expression vector under the 2'-5'-oligoadenylate synthetase gene (OAS) promoter (pGL3-OAS-re-caspase-3) and demonstrated that it is an effective gene therapy for HCV core-positive liver cells in vitro.
46	22159511	Tumor-bearing mice were treated with an intratumoral injection of pGL3-OAS-re-caspase-3.
47	22159511	The subcutaneous hepatoma in vivo mouse models stably expressing HCV core protein and co-expressing HCV core protein and pGL3-OAS-re-caspase-3 were established.
48	22159511	Double-label immunofluorescence staining showed that the percentage of co-expression of both HCV core and caspase-3 was 76 ± 6% in the group treated with pGL3-OAS-re-caspase-3.
49	22159511	There was a significant increase in the number of apoptotic cells in the group treated with the pGL3-OAS-re-caspase-3 system by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and transmission electron microscopy.
50	22159511	The results suggest that the pGL3-OAS-re-caspase-3 construct can effectively induce apoptosis in HCV core-positive hepatocytes in vivo.
51	22159511	The results presented strongly suggest that the transfer of pGL3-OAS-re-caspase-3 is an effective and promising gene therapy strategy for HCV infection.